Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
--NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI -- -- SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris -- -- Company...
-
BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
-
BOSTON, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
-
-- MAA submission for both community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) -- -- EMA decision expected second half of 2019 -- BOSTON,...
-
BOSTON, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
-
– Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) specifically designed to overcome tetracycline...
-
– To be launched in U.S. by Almirall SA – Paratek earns $12 million milestone payment BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical...
-
BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
-
BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be presented at...
-
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...